Haemonetics (HAE) Tops Q2 EPS by 7c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Haemonetics (HAE) PT Raised to $59 at Jefferies; Reiterates Buy
November 8, 2017 9:08 AM ESTJefferies raised its price target on Haemonetics (NYSE: HAE) to $59.00 (from $48.00) while maintaining a Buy rating. The upgrade cycle for NexSys appears underway with several customers launching trials in September while full market release mid-next year assumes new contracts are in place.
The... More
Haemonetics (HAE) PT Raised $50 at Craig-Hallum
November 8, 2017 8:02 AM ESTCraig-Hallum raised its price target on Hold-rated Haemonetics (NYSE: HAE) to $50.00 (from $40.00).
Analyst Matthew Hewitt said the turnaround appears on track and cash flow is improving.
For an analyst ratings summary and ratings history on Haemonetics... More
